Bryce Point Capital LLC Invests $513,000 in Tandem Diabetes Care, Inc. $TNDM

Bryce Point Capital LLC bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 42,258 shares of the medical device company’s stock, valued at approximately $513,000.

Other large investors have also added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in Tandem Diabetes Care by 30.5% in the 1st quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company’s stock worth $4,054,000 after purchasing an additional 49,408 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Tandem Diabetes Care by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company’s stock valued at $1,426,000 after purchasing an additional 2,096 shares in the last quarter. Millennium Management LLC increased its position in shares of Tandem Diabetes Care by 41.1% during the first quarter. Millennium Management LLC now owns 227,585 shares of the medical device company’s stock valued at $4,361,000 after buying an additional 66,245 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Tandem Diabetes Care in the first quarter worth about $225,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Tandem Diabetes Care by 5.0% in the first quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company’s stock worth $13,653,000 after buying an additional 34,069 shares during the period.

Analyst Ratings Changes

TNDM has been the topic of a number of research analyst reports. Mizuho upped their target price on Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, December 17th. Stifel Nicolaus lifted their price target on Tandem Diabetes Care from $16.00 to $20.00 and gave the company a “hold” rating in a research report on Wednesday, February 4th. TD Cowen initiated coverage on Tandem Diabetes Care in a research note on Tuesday, January 27th. They issued a “buy” rating and a $25.00 price target on the stock. Canaccord Genuity Group set a $35.00 price objective on Tandem Diabetes Care and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Citigroup boosted their target price on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $24.35.

Tandem Diabetes Care Stock Down 1.5%

Shares of NASDAQ:TNDM opened at $18.89 on Tuesday. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33. The stock has a fifty day simple moving average of $21.10 and a two-hundred day simple moving average of $16.80. Tandem Diabetes Care, Inc. has a 12-month low of $9.98 and a 12-month high of $36.58. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.19 and a beta of 1.68.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.